Condition: Gaucher Disease Type 3 · Sponsor: Azafaros B.V.
A 96-week, open-label, Phase 2 study to evaluate the efficacy and safety of Nizubaglustat (AZ-3102) in patients with Gaucher disease type 3 (GD3).
This description comes directly from the study's public registry record.
Patient Advocacy Representative · Please reach out by email · info@azafaros.com
Contact for Healthcare Professionals · Please reach out by email · medinfo@azafaros.com
Always discuss trial participation with your own doctor first.
| SMS Medical College Jaipur | Jaipur, India | — |
| Maula a Azad medical college Delhi | New Delhi, India | — |
| Sir Ganga Ram Hospital | New Delhi, India | — |
| University of Child Health Sciences and the Children's Hospital | Lahore, Pakistan | — |
| Clininal Trial Unit, Rehman Medical Institute | Peshawar, Pakistan | — |
| Ege Universitesi Tip Fakultesi Hastanesi | Bornova, İzmir, Turkey (Türkiye) | — |
| Gazi University Medical Faculty Hospital | Yenimahalle, Turkey (Türkiye) | — |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07715084